Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
These dynamics can rattle even the most seasoned professionals, which is why we started StockStory – to help you separate the good companies from the bad. Keeping that in mind, here is one mid-cap stock with massive growth potential and two best left ignored.
Two Mid-Cap Stocks to Sell:
Snap-on (SNA)
Market Cap: $20.24 billion
Founded in 1920, Snap-on (NYSE:SNA) is a global provider of tools, equipment, and diagnostics for various industries such as vehicle repair, aerospace, and the military.
Why Does SNA Worry Us?
-
Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
-
Flat earnings per share over the last two years lagged its peers
-
Eroding returns on capital suggest its historical profit centers are aging
Snap-on is trading at $392.84 per share, or 19x forward P/E. Check out our free in-depth research report to learn more about why SNA doesn’t pass our bar.
Corcept (CORT)
Market Cap: $13.09 billion
Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ:CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases.
Why Are We Hesitant About CORT?
-
Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 16.1% annually
-
Free cash flow margin dropped by 25.7 percentage points over the last five years, implying the company became more capital intensive as competition picked up
-
Diminishing returns on capital suggest its earlier profit pools are drying up
At $121.44 per share, Corcept trades at 26.6x forward P/E. Read our free research report to see why you should think twice about including CORT in your portfolio, it’s free.
One Mid-Cap Stock to Buy:
JFrog (FROG)
Market Cap: $11.06 billion
Named after the amphibian that continuously evolves from egg to tadpole to adult, JFrog (NASDAQ:FROG) provides a platform that helps organizations securely create, store, manage, and distribute software packages across any system.
What Makes FROG Stand Out?
